Current Edition

Europe

Medicines Co. awaits its date with destiny

Investors in The Medicines Company have Sept. 2 circled in red on their calendars. That's the day the company plans to report the first pivotal results from late-...
Continue Reading →
news

Regeneron gets cholesterol drug win where Praluent won’t go

(Credit: Flickr; Helge V. Keitel ) Regeneron Pharmaceuticals said its experimental drug evinacumab significantly lowered "bad" cholesterol levels 49% compared to...
Continue Reading →
news

Roche cancer drug the 3rd approved for pan-tumor use

(Credit: Roche ) For the third time, the Food and Drug Administration cleared a cancer drug to treat tumors based on a specific genetic signature rather than by ...
Continue Reading →
Europe

Study finds lack of racial diversity in cancer drug clinical trials

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers fro...
Continue Reading →
Europe

Regeneron’s Eylea snags prefilled syringe approval as Novartis rival looms

Regeneron's Eylea scored a nod for a prefilled injector application to treat four retinal conditions. (Regeneron) Eye med Eylea has been a blockbuster sales forc...
Continue Reading →
news

New drug shows encouraging survival in pancreatic cancer

A clinical trial testing a new drug in pancreatic cancer had promising initial results, report researchers from the University of Michigan Rogel Cancer Center. A ph...
Continue Reading →
Europe

AZ, Merck’s latest Lynparza combo win could widen its ovarian cancer reach

The PARP inhibitor Lynparza is in a three-way market battle with GSK's Zejula and Clovis' Rubraca. (AstraZeneca) In the red-hot market for PARP inhibitors, Astra...
Continue Reading →
Europe

Study success strengthens case for Lynparza in ovarian cancer

(Credit: AstraZeneca ) Adding AstraZeneca's Lynparza to Roche's older cancer drug Avastin helped women with advanced ovarian cancer live longer without their tum...
Continue Reading →
news

Deciphera success sets up 2-horse race in gastrointestinal cancer

Deciphera Pharmaceuticals' ripretinib kept patients with advanced gastrointestinal stromal tumors (GIST) from progressing significantly longer than those on placebo,...
Continue Reading →
news

As Ebola outbreak rages, researchers find promise in Regeneron drug

(Credit: Flickr, NIAID ) Two experimental Ebola treatments, including a drug from Regeneron, are advancing to the next stage of a large clinical trial after an i...
Continue Reading →